Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Open accessThe DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
RetractedZhang, D., Qiu, X., Li, J., Zheng, S., Li, L., & Zhao, H. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1556064 · Cited by 72
RetractedBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Cited by
Items 301–400 of 436
Saeidi, Y., Ghorbani, M., Najafi, A., & Moghaddam, M. M. (2025) · Iranian journal of pathology · doi:10.30699/ijp.2025.2067802.3499 · Cited by 1
“FGF1 and FGF2 are involved in cell proliferation and angiogenesis (26), while EGFR regulates crucial signaling pathways such as MAPK and PI3K-Akt, making it a promising therapeutic target (27, 28).”
Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes
Gao, Y., Zeng, B., Wang, Z., Liang, S., & Yang, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1663835 · Cited by 1
“Their regulatory modes exhibit marked variations depending on metabolite type, tumor tissue origin, and pathway microenvironment (Fang and Richardson, 2005; Guo Y.-J. et al., 2020; Stefani et al., 2021).”
Body shape phenotype, TYG trajectory and the risk of digestive system cancers
Kai, Z., Liu, C., Zhang, Q., Wu, S., & Yun, K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1658356 · Cited by 1
“When insulin resistance and hyperinsulinemia are present, IGF receptors are overly activated, leading to a cascade of downstream PI3K/AKT and RAS/MAPK signaling, causing uncontrolled cell proliferation (32).”
Fatehi, R., Abbasi, E., Khosravian, F., Salehi, M., & Kazemi, M. (2025) · Advanced Biomedical Research · doi:10.4103/abr.abr_278_23 · Cited by 1
Pal, S., Panda, A., Bhowmick, B., & Bera, K. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100714 · Cited by 1
Zhang, H., Wang, C., Fan, J., Chen, Z., Yu, H., Bai, Y., Zhang, T., Zhu, Q., Feng, Y., Niu, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202503924 · Cited by 2
Tang, K. L., Cheng, Y., Gong, J., & Li, Y. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114868 · Cited by 1
Chen, X., Yang, M., Luo, X., & Yuan, X. (2026) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.12.002 · Cited by 1
“…SNHG5 – GNB2 – Wnt axis has not previously been systematically explored in CRC. Importantly, PI3K/AKT signaling is intricately linked to chemotherapy resistance, metabolic adaptation, and immune evasion [54], suggesting that the SNHG5 – GNB2 axis may have broader implications beyond EMT regulation.”
Huang, C.-J., & Kb, C. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153343 · Cited by 1
Graziosi, A., Ghelli, L., Corrieri, C., Iacenda, L., Manfredi, M. C., Angelini, S., Sita, G., Hrelia, P., & Morroni, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031134 · Cited by 1
“EGFR1 and IGF1R-1 are tyrosine kinase receptors that are key components of the PI3K/AKT/mTOR axis, which regulates cell growth, proliferation, differentiation, and survival [27,38,39].”
Rodriguez, V., Villani, A., Sénica, M., Panebianco, C., Pazienza, V., & Preto, A. (2026) · Cancers · doi:10.3390/cancers18030369 · Cited by 1
“These oncogenic mutations activate downstream signaling pathways, most notably, phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK), which regulate cell proliferation, differentiation, and survival [24–31].”
Tao, H., Wang, Y., Wang, F., Hu, X., & Wang, C. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04244-5 · Cited by 1
“Growth factors, cytokines, and insulin all activate Akt, alternatively, known as protein kinase B, leading to the phosphorylation of various substrates that promote cell proliferation, survival, and inhibit apoptosis [27, 28].”
Zhang, T., Li, L., & Du, C. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5857 · Cited by 1
“Following internalization, IGF‑1R can sustain the activation of downstream signaling pathways, such as PI3K/AKT/mTOR and MAPK/ERK, from subcellular compartments, including endosomes and lysosomes (113).”
Wirasisya, D. G., Kincses, A., Setiawansyah, A., Barta, A., Chang, F., & Hohmann, J. (2026) · Pharmaceutical Biology · doi:10.1080/13880209.2026.2629733 · Cited by 1
“This kinase pattern is consistent with established mechanisms in colorectal cancer pathogenesis, in which dysregulation of MAPK, PI3K/AKT, and protein kinase C drives proliferation, survival, and metastasis (Stefani et al. 2021; Song et al. 2024).”
P62 in colorectal cancer: from inflammation suppression to cancer promotion
Niumuqie, A., Huang, J., Liu, L., Chen, H., Chen, J., Zou, S., Pang, Y., Wu, X., Liu, M., & Liang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760631 · Cited by 2
Centeno‐Girona, H., Acevedo, S. N. L., Zenón-Meléndez, C. N., Diaz-miranda, O. L., & Caraballo, E. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083666 · Cited by 1
Menaga, S., & Geetha, N. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70220 · Cited by 1
“The PI3K/AKT/mTOR pathway, which responds to growth factors, hormones, and nutrient signals, also plays a central role in sustaining tumor growth and proliferation [ 8].”
Begum, J., Bhunia, S., Chatterjee, S., Chakraborty, T., DE, P. K., & Kundu, M. (2026) · Medicine in Microecology · doi:10.1016/j.medmic.2026.100175 · Cited by 1
Wrasidlo, W., & Masliah, E. (2026) · Cells · doi:10.3390/cells15131177 · Cited by 2
“…model is context-dependent; for example, malignancies secrete overlapping repertoires of growth factors, such as IGF-1, VEGF, BDNF, TGF-β , and FGFs [164], which promote https://doi.org/10.3390/cells15131177 neuronal survival and proteostatic pathways relevant to AD, LBD, and FTLD [165].”
InfluentialApplication of Nanotechnology in Cancer Diagnosis, Biomarker Discovery, and Drug Discovery
Nair, A., Prasad, A. P., Shajahan, H., Sivasree, M., Somasundaram, D. B., & Yesupatham, S. K. (2026) · Studies in Rhythm Engineering · doi:10.1007/978-981-95-7012-6_4 · Cited by 1
Antibody-drug conjugates in colorectal cancer: advances, challenges, and prospectives
Zeng, L., Zhu, Y., Zhang, K., Liu, B., & Ding, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118270 · Cited by 1
Palenca, I., Sanseverino, W., Malinverni, R., Vincenzi, M., Beaufils, G., Spica, V. R., Valeriani, F., Sarnelli, G., & Esposito, G. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119838 · Cited by 1
PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation
Shi, Q., Liu, J., Chu, Q., Zeng, Y., Zhang, Y., Jiang, S., Yuan, X., Zhu, D., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02770-w · Cited by 1
“202,203 Impor-tantly, mutations in the PIK3CA gene are prevalent in various human cancers, with ~30% of CRC cases harboring these mutations.”
Radu, F. I., Sîrbu, C. A., Axelerad, A. D., & Ștefan, I. (2022) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2022.125.3.16 · Cited by 3
Wang, J., & Han, B. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1089 · Cited by 1
The Impact of the Hypercaloric Diet versus the Mediterranean Diet on Insulin Sensitivity
Radu, F. I., Ranetti, A.-E., Vasile, M., Sirbu, A. M., Axelerad, A. D., & Sîrbu, C. A. (2023) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2023.126.3.6 · Cited by 1
Magnesium Lithospermate B Inhibits Colorectal Cancer Cell Progression Through JAK2-STAT3 Signaling
Huo, D., Zhang, J., Ma, T., Liu, Y.-M., Zhang, J., Dong, B., Wu, A., Wu, A., Jin, Z., & Li, Y. J. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0071 · Cited by 1
SN promote retinal pathological neovascularization through activation of EGFR, IR and IGF-1R
Deng, W., Huang, K., Cui, L., Niu, Z., Ke, D., Jiang, L., Tang, N., Zhong, H., Lan, Q., Xu, F., et al. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110158 · Cited by 1
Wang, W., Cheng, Y., Meng, Q., Jia, B., Yao, D., & Cheng, Y. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03552-w · Cited by 1
“These pathways are closely related to cell cycle regulation, metabolism, and anti-apoptosis [45].”
Xu, M., Jin, X., & Shen, Z. (2024) · Open Life Sciences · doi:10.1515/biol-2022-1007 · Cited by 1
Trujillo-Fernández, Y. G. V., Rodríguez-Torres, D. E., Tovar-Jácome, C. D. J., Barros‐Núñez, P., Godínez-Rodríguez, M. Y., Pérez-Bojórquez, P. J., Flores-Martínez, L. A., Pineda-Razo, T. D., Marín-Contreras, M. E., Alcaraz-Wong, A. A., et al. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.71.3.4 · Cited by 1
“The role of the rs7512692 and rs4655646 variants in miR-3117 gene regarding cancer has only been investigated in acute lymphoblastic leukemia [22] and breast cancer [23].”
Mehranfard, N., Rezazadeh, H., Soltani, N., Dastgerdi, A. H., Rad, M. G., & Ghasemi, M. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/5703718 · Cited by 1
Han, L., Lin, L., Chen, J., & Yan, B. (2023) · Studies in health technology and informatics · doi:10.3233/shti230856
Rozati, R., Mohiuddin, N., Ayapati, V. A., Tabasum, W., Mehdi, A. G., Ahmed, T. N., Nayela, S., Khan, A. A., Mohammad, A., & Ali, A. (2023) · Gynecology & Reproductive Health · doi:10.33425/2639-9342.1236
Yan, Y., Zhang, X., & Tian, T. (2023) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm58861.2023.10386003
“However, it’s important to recognize that the MAPK pathway is not a singular, isolated pathway but rather a part of a complex network of signaling pathways that interact and cross-talk with each other [12].”
BackgroundOchioni, A. C., Panzenhagen, P., Vieira, C. P., & Conte‐Júnior, C. A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_264
Li, W., Xu, J., Wen, Z., Zhong, Q., Deng, N., Sun, X., Jiang, Y., & Wang, Y. (2024) · Colorectal Cancer · doi:10.1080/1758194x.2024.2362614
Expression of PDZD4 in colorectal cancer and its impact on colorectal cancer progressionPreprint
Yu, Z., Wang, Z., Wang, H., Huang, Y., & Lai, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4538251/v1
Jo, H. H. (2024) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2024.12.2.82
Kumar, A., Mohit, M., Pandey, A. K., Jain, M., Shrivastava, A., Shyam, H., Sahu, D. K., Mishra, A., Singh, S., & Singh, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23881-9.00004-9
Wahyuni, R. S., Muchlisin, M. A., Jamil, A. S., Astuti, E. J., & Rafikayanti, A. (2024) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v7i3.6988
“Key signaling pathways implicated in cancer include the MAPK and PI3K-Akt pathways, which regulate cell proliferation, survival, and metastasis 69,70 .”
BackgroundBarbosa, J. V., Crispim, A. A., Sousa, J., Pereira, K. M. A., Sousa, F. B., da Cunha, M. D. P. S. S., Silva, P. G. D. B., & Dantas, T. S. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.11.3807
“Additionally, studies have indicated that the PI3K/AKT /mTOR pathway may contribute to resistance to chemotherapy and radiotherapy, which could result in a poorer prognosis and, subsequently, reduced overall survival [26-28].”
Moreau, G. B., Young, M., Behm, B. W., Tanyüksel, M., Ramakrishnan, G., & Petri, W. A. (2024) · medRxiv · doi:10.1101/2024.11.28.24318101 · Cited by 1
Chang, L., Kang, Y., Zhu, M., Liu, J., Lan, C., & Xu, Q. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5044981
Influence du microbiote intestinal sur la régulation de l'immunosurveillance du cancer
del Socorro, T. P. (2024) · theses.fr (ABES) · doi:10.70675/232b3261z2813z464cz830dz0aed33c39ce7
Ismail, H. M., & Shatat, A.-A. S. (2025) · German Journal of Pharmaceuticals and Biomaterials · doi:10.5530/gjpb.2024.4.12 · Cited by 1
Zhang, P., Li, S., Zhang, P., & Sun, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-5941352/v1
Genetic Signatures Upon Transition from Colorectal Polyps to colon Cancer
Radak, M., Ravand, F. K., Ghamari, N., & Fallahi, H. (2025) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-025-00060-1
“In summary, cir-cRNAs play crucial roles in CRC development and progression, and ongoing research aims to unravel their intricate functions and harness their therapeutic potential [1, 110, 111].”
RAMAMOORTHY, S., Ramasamy, J., Gopinath, S., VIJAYAN, N., & Jaisankar, D. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i4.54115
Mahecha-Ortíz, J. D., Enríquez‐Flores, S., la Mora, I. D. L. M. D., Flores-López, L. A., Gutiérrez‐Castrellón, P., López‐Velázquez, G., Sánchez-Mora, R., & García‐Torres, I. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109055
PATHOGENESIS AND MOLECULAR-GENETIC ASPECTS OF SALIVARY GLAND TUMORS
Rizaev, J., & Akhrorov, A. (2025) · Medical science of Uzbekistan · doi:10.56121/2181-3612-2025-2-155-160
NELFCD Promotes Colon Cancer Progression by Regulating the DUSP2–p38 Axis
Dai, W., Zhu, M., Sun, Y., Xu, B., Ma, G., Shi, H., & Li, P. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25221
Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy
Zeng, Z., Ke, Y., Huang, F., Li, H., Zhang, X., Li, D., Wu, Y., Chen, T., & Zhen, Y.-H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14357-9 · Cited by 2
Wang, C., Peng, Y., Yang, H., Jiang, Y., Khalid, A. K., Zhang, K., Xie, S., Bermudez, L. E., Yang, Y., Zhang, L., et al. (2025) · eLife · doi:10.7554/elife.107132.1
Zhang, H., Liu, Y., Wang, J., wang, S., Xue, G., Zhi, Y., Miao, M., Fang, X., Wu, J., Wang, H., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5323846
Harnessing apigenin for breast cancer treatment: Current insights
Kumar, R., & Shivakumar, S. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201454 · Cited by 1
Liang, C., Wang, J., & Liu, X. (2025) · International Journal of Genomics · doi:10.1155/ijog/3881424
“Studies have shown that all three major subfamilies of the PI3K/Akt/mTOR signaling pathway may be activated by growth factors and will further play a key role in CRC development [60].”
Yao, M., Wang, R., Cui, R., Lou, F., & Chen, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03476-1
“However, these treatments are often accompanied by side effects, including decreased gastrointestinal function, poor immunity, and worse pain [26].”
Molecular crossroads: identifying MAPK proteins bridging SMAD and dopamine pathways in breast cancer
Borawski, P., Sirek, T., Sirek, A., Zmarzły, N., Nowakowski, R., Ossowski, P., Chalcarz, M., Boroń, K., Boroń, D., Bereza, K., et al. (2025) · Cell Cycle · doi:10.1080/15384101.2025.2549097
“However, the precise molecular intermediates bridging these pathways remain unidentified [25,26,30].”
Wang, C., Peng, Y., Yang, H., Jiang, Y., Khalid, A. K., Zhang, K., Xie, S., Bermudez, L. E., Yang, Y., Zhang, L., et al. (2025) · eLife · doi:10.7554/elife.107132.2
Is it Possible to Use a Platelet Rich Plasma (PRGF-ENDORET®) in Case of Oral Metastatic Lesions?
Giacomello, M. S., Giacomello, A., Rescigno, E., Lucchina, A. G., & Mortellaro, C. (2025) · Medical Research Archives · doi:10.18103/mra.v13i8.6789
Li, H.-G., Gao, P., Wang, Q., Xu, C., & Xue, F. (2025) · Digestion · doi:10.1159/000548266 · Cited by 1
“These pathways play pivotal roles in CRC progression and recurrence [20–23].”
Tran, P. L., Tang, Y., Hsu, J.-W., & Lee, T.-Y. (2025) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb66090.2025.11177121
“Activation of PI3K-Akt signaling in glioma cells enhances survival by inhibiting pro-apoptotic factors and driving cell cycle progression [35].”
Oncogenic Role of EEPD1 via Protein Kinase B Phosphorylation in Colorectal Cancer
Ma, R., Shimura, T., Yin, C., Huang, Y., Kitajima, T., Yamashita, S., Higashi, K., Sato, Y., Kawamura, M., Koike, Y., et al. (2025) · Journal of Surgical Research · doi:10.1016/j.jss.2025.09.067
Loganathan, S., Hashim, N. M., Wan‐Ibrahim, W. I., & Rashid, N. N. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100414
Zhou, R., Zeng, Z., Xu, Y., Tang, Q., Zhang, S., & Zhu, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-04166-8
“In our KEGG analysis, the pathway predominantly involved was the PI3K-Akt signaling pathway, which regulates cellular proliferation, differentiation, and survival [28].”
Chang, S.-Y., Gu, B., Xiong, Y., Zhao, M.-S., Li, L., Liu, Y., Wang, B., Li, G., Du, R., & Zhang, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00375-3
“Frequent mutations in critical components not only serve as essential diagnostic biomarkers but also establish this pathway as a pivotal target for therapeutic intervention [6, 7].”
ARMH4 accelerates aging by maintaining a positive-feedback growth signaling circuit
Fang, Y., Wang, B., Guo, Q., Lv, J., Li, J., Wang, J., Guo, N., Bai, Y., Xu, A., Ma, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67505-x
Multi-omics integration and network analysis identify therapeutic hub genes in colorectal cancer
Mathew, E., Thomas, P. L. L., & Mathew, L. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00696-x
Bublitz, N.-A. (2024) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/29059 · Cited by 1
Dawoud, M. M., Salah, M., & Mohamed, A. S. E. D. (2024) · Figshare · doi:10.6084/m9.figshare.26594018
Yan, S., Zhao, J., Gao, P., Li, Z., Li, Z., Liu, X., & Wang, P. (2024) · Figshare · doi:10.6084/m9.figshare.26678588
Uncover the mechanism of action of new FeCp compounds in colorectal cancer cells
Silva, A. P. P. D. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/nvh9-6s02
Yan, S., Zhao, J., Gao, P., Li, Z., Li, Z., Liu, X., & Wang, P. (2024) · Figshare · doi:10.6084/m9.figshare.26678591
Diabetes mellitus and antithrombotic treatment
Τζάνη, Χ. Κ., & Τζάνη, Χ. Κ. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.40788
Manea, M. (2025) · eScholarship@McGill (McGill) · doi:10.82308/34382
Hou, H., Zhang, L., & Duan, H. (2025) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2025058410
Proteomics, metabolomics, and precision medicine
Kamal, G. M., Abid, F., Badshah, Y., & Shabbir, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34671-2.00008-6
Gómez-Torres, I. (2025) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
SO‘LAK BEZLARI O‘SMALARINING PATOGENEZI VA MOLEKULAR-GENETIK JIHATLARI
O‘g‘li, E. Z. N. (2025) · Research Focus International Scientific Journal · doi:10.66073/researchfocus.v4i6.1712 · Cited by 1
“Ushbu signallar kaskadlarining disrеgulyatsiyasi xavfli fenotipning rivojlanishiga yordam beradi va ularni davolash uchun istiqbolli nishonlar (targets) sifatida ko‘rsatadi [12,13,14].”
Al-Bahri, A. K., Zadjali, F., Hanif, S., Alharthi, Z., Sakr, H. F., & Al-Kharusi, A. (2026) · Cancers · doi:10.3390/cancers18010171
Shan, T.-J., Li, L., Wan, X., Yi-zhi, L., Jiang, T., Chen, Z.-L., Yu, X., & Cheng, Y. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01673-w
de Sousa, V. M. (2025) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Shi, F., Wu, X., Cai, D., Zhang, F., & Zhang, Y. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025601053
Yin, Y., Li, X., Xie, Y., Liu, S., Tan, S., & Xu, C. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01091-6
“Mecha-nistically, João Figueira Scarini et al. [29] found that the binding of EphA receptors with Eph receptors activates the MAPK/ERK [30] and PI3K/AKT [31, 32] signaling pathways.”
Gong, Y. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.3.reg.15231.1
李, 志. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162527
Vastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7039954/v1
Yang, Q., Zhao, J., Liu, X., Liu, J., Chen, Y., Mai, J., & Hong, M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04683-0
Feng, C., Yang, C., Gao, W., Liu, Y., Wei, J., Shen, C., Chen, W., & Li, X. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05097-z
“The PI3K/AKT pathway can be the driving factor because it is frequently over-activated in colorectal cancer (Hoxhaj et al 2020; Stefani et al. 2021), and this over-activation is caused by many factors, such as the gene PIK3CA, responsible for encoding p110α, gain-of-function mutations in cancer…”
Yue, Y., Ma, Y., Du, L., Jin, Y., Si, Z., Fang, H., Liu, H., Zhu, H., Liu, Y., & Chen, P. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103155
Yasir, M., Patra, J., Maurya, R. K., Tripathi, A. S., & Hasan, T. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100273
Mapping the various signaling pathways in cancer
Sharma, V., Kumar, A., Behl, T., Arora, S., Sharma, N., & Singh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00011-x
Santra, A., Gouthami, K., Maity, S., Surtineni, V. P., Nagajyothi, P. C., Shim, J., Arjunan, S., & Reddy, V. D. (2026) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ae4fbf
“Due to these dysregulations, it creases cell proliferation, and more importantly, altered metabolic pathways [ 92, 93 ] .”
Étude épidémiologique et moléculaire des cancers colorectaux dans une région de l’ouest Algérien
Dahmani, B. (2024) · Dépôt Institutionnel de lUniversité de Tlemcen
Edwards, G. O., Causi, F. S. L., Castagnola, G., Singh, S., & Amendola, P. G. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1777400
Xu, Q., Dong, M., Yuan, Y., & Zhang, Q. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01162-6
Huang, S. J., Xiao, Z., Zhao, R., Li, Z., Ling, J., Deng, G., Wang, Y., Zhao, Q., Gao, H., & Li, K. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109031
Naidoo, V., Achilonu, I., Soobben, M., Iwuchukwu, E. A., Singh, N., Kandhavelu, J., Hull, R., Mirza, S., & Penny, C. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073240
Life inside the cell: A modern review of cellular physiology and molecular regulation
Kurniawan, M. ‘., Khairullah, A. R., Sukmanadi, M., Pratama, B. P., Prihandani, S. S., Mustofa, I., Ansori, A. N. M., Kurniasih, D. A. A., Rehman, S., Ma’ruf, I. F., et al. (2026) · Journal of Advanced Veterinary Research/Journal of Advanced Veterinary Research · Cited by 2
Metadata
- Authors
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M.
- Affiliations
- Department of Family Medicine and Clinical Base, ‘‘Dr. Carol Davila’ Central Military Emergency University Hospital, 051075 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Miricescu, Daniela
- Greabu, Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-23
- Volume
- 22
- Issue
- 19
- Pages
- 10260
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508474
- OpenAlex
- W3200117713
- Cited by
- 402
- References
- 206
- Citations by year
- 2026: 69 · 2025: 134 · 2024: 103 · 2023: 68 · 2022: 26 · 2021: 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, growth factors, PI3K/AKT/mTOR pathway, MAPK signaling, tumor microenvironment, EGFR, IGF-1 receptor, VEGF-A, growth factor inhibitors, colorectal cancer risk factors, colorectal cancer pathogenesis, cell proliferation and invasion
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

